Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry

Bioconjugate Chemistry

Volumn 23, Issue 6, 2012, Pages 1252-1258

  Francis, J Nicholas ^a   Redman, Joseph S ^a   Eckert, Debra M ^a   Kay, Michael S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; PEPTIDES; SCAFFOLDS;

DESIGN STRATEGIES; EFFICIENT OPTIMISATION; EFFICIENT SYNTHESIS; LOCALISED; MODULARS; MULTIMERIC; PEPTIDE INHIBITORS; RAPID-PROTOTYPING; SCAFFOLDS DESIGN; TETRAMERIC;

OLIGOMERS;

CHOLESTEROL; MODULAR TETRAMERIC SCAFFOLD; MOLECULAR SCAFFOLD; PIE12 TRIMER; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ABSORPTION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONJUGATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG RESISTANCE; DRUG SYNTHESIS; ENERGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMBRANE BINDING; MUTATION; PEPTIDE SYNTHESIS; PROCESS OPTIMIZATION; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; VIRUS ENTRY; VIRUS INHIBITION;

ANTI-HIV AGENTS; DRUG DESIGN; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PEPTIDES; VIRUS INTERNALIZATION;

EID: 84862699298     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300076f     Document Type: Article

References (48)

1. Freed, E. O., and Martin, M. A. (1995) The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J. Biol. Chem. 270, 23883-6.
2. Eckert, D. M., and Kim, P. S. (2001) Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777-810.
3. Jones, P. L., Korte, T., and Blumenthal, R. (1998) Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J. Biol. Chem. 273, 404-9.
4. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-73.
5. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-30.
6. Root, M. J., Kay, M. S., and Kim, P. S. (2001) Protein design of an HIV-1 entry inhibitor. Science 291, 884-8.
7. Jiang, S., Lin, K., Strick, N., and Neurath, A. R. (1993) HIV-1 inhibition by a peptide. Nature 365, 113.
8. Wild, C., Oas, T., McDanal, C., Bolognesi, D., and Matthews, T. (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U. S. A. 89, 10537-41.
9. Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., and Matthews, T. J. (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 91, 9770-4.
10. Rimsky, L. T., Shugars, D. C., and Matthews, T. J. (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72, 986-93.
11. Golding, H., Zaitseva, M., de Rosny, E., King, L. R., Manischewitz, J., Sidorov, I., Gorny, M. K., Zolla-Pazner, S., Dimitrov, D. S., and Weiss, C. D. (2002) Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J. Virol. 76, 6780-90.
12. Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A. 95, 15613-7.
13. Eckert, D. M., Malashkevich, V. N., Hong, L. H., Carr, P. A., and Kim, P. S. (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99, 103-15.
14. Pollard, V. W., and Malim, M. H. (1998) The HIV-1 Rev protein. Annu. Rev. Microbiol. 52, 491-532.
15. Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Zhang, Z., O'Brien, W. A., Ratner, L., Shaw, G. M., and Hunter, E. (2001) Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75, 8605-14.
16. Eggink, D., Baldwin, C. E., Deng, Y., Langedijk, J. P., Lu, M., Sanders, R. W., and Berkhout, B. (2008) Selection of T1249-resistant human immunodeficiency virus type 1 variants. J. Virol. 82, 6678-88.
17. Eggink, D., Bontjer, I., Langedijk, J. P., Berkhout, B., and Sanders, R. W. (2011) Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J. Virol. 85, 10785-97.
18. Ray, N., Harrison, J. E., Blackburn, L. A., Martin, J. N., Deeks, S. G., and Doms, R. W. (2007) Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol. 81, 3240-50.
19. Reeves, J. D., Lee, F. H., Miamidian, J. L., Jabara, C. B., Juntilla, M. M., and Doms, R. W. (2005) Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 79, 4991-9.
20. Lalezari, J. P., Bellos, N. C., Sathasivam, K., Richmond, G. J., Cohen, C. J., Myers, R. A., Jr., Henry, D. H., Raskino, C., Melby, T., Murchison, H., Zhang, Y., Spence, R., Greenberg, M. L., Demasi, R. A., and Miralles, G. D. (2005) T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J. Infect. Dis. 191, 1155-63.
21. Welch, B. D., Francis, J. N., Redman, J. S., Paul, S., Weinstock, M. T., Reeves, J. D., Lie, Y. S., Whitby, F. G., Eckert, D. M., Hill, C. P., Root, M. J., and Kay, M. S. (2010) Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol. 84, 11235-44.
22. Welch, B. D., VanDemark, A. P., Heroux, A., Hill, C. P., and Kay, M. S. (2007) Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. U. S. A. 104, 16828-33.
23. Milton, R. C., Milton, S. C., and Kent, S. B. (1992) Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity. Science 256, 1445-8.
24. Kahle, K. M., Steger, H. K., and Root, M. J. (2009) Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog. 5, e1000674.
25. Platt, E. J., Durnin, J. P., and Kabat, D. (2005) Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J. Virol. 79, 4347-56.
26. Steger, H. K., and Root, M. J. (2006) Kinetic dependence to HIV-1 entry inhibition. J. Biol. Chem. 281, 25813-21.
27. Ingallinella, P., Bianchi, E., Ladwa, N. A., Wang, Y. J., Hrin, R., Veneziano, M., Bonelli, F., Ketas, T. J., Moore, J. P., Miller, M. D., and Pessi, A. (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. U. S. A. 106, 5801-6.
28. Porotto, M., Rockx, B., Yokoyama, C. C., Talekar, A., Devito, I., Palermo, L. M., Liu, J., Cortese, R., Lu, M., Feldmann, H., Pessi, A., and Moscona, A. (2010) Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog. 6, e1001168.
29. Porotto, M., Yokoyama, C. C., Palermo, L. M., Mungall, B., Aljofan, M., Cortese, R., Pessi, A., and Moscona, A. (2010) Viral entry inhibitors targeted to the membrane site of action. J. Virol. 84, 6760-8.
30. Rajendran, L., Schneider, A., Schlechtingen, G., Weidlich, S., Ries, J., Braxmeier, T., Schwille, P., Schulz, J. B., Schroeder, C., Simons, M., Jennings, G., Knolker, H. J., and Simons, K. (2008) Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science 320, 520-3.
31. Teruya, K., Nishizawa, K., and Doh-ura, K. (2010) Semisynthesis of a protein with cholesterol at the C-terminal, targeted to the cell membrane of live cells. Protein J. 29, 493-500.
32. Lee, H., Venable, R. M., Mackerell, A. D., Jr., and Pastor, R. W. (2008) Molecular dynamics studies of polyethylene oxide and polyethylene glycol: hydrodynamic radius and shape anisotropy. Biophys. J. 95, 1590-9.
33. Wexler-Cohen, Y., Ashkenazi, A., Viard, M., Blumenthal, R., and Shai, Y. (2010) Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. FASEB J. 24, 4196-202.
34. Wexler-Cohen, Y., and Shai, Y. (2007) Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J. 21, 3677-84.
35. Wexler-Cohen, Y., and Shai, Y. (2009) Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. PLoS Pathog. 5, e1000509.
36. Bader, B., Kuhn, K., Owen, D. J., Waldmann, H., Wittinghofer, A., and Kuhlmann, J. (2000) Bioorganic synthesis of lipid-modified proteins for the study of signal transduction. Nature 403, 223-6.
37. Peisajovich, S. G., Gallo, S. A., Blumenthal, R., and Shai, Y. (2003) C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J. Biol. Chem. 278, 21012-7.
38. Luo, C., Wang, K., Liu de, Q., Li, Y., and Zhao, Q. S. (2008) The functional roles of lipid rafts in T cell activation, immune diseases and HIV infection and prevention. Cell Mol. Immunol. 5, 1-7.
39. Waheed, A. A., and Freed, E. O. (2010) The Role of Lipids in Retrovirus Replication. Viruses 2, 1146-1180.
40. Vincent, N., Genin, C., and Malvoisin, E. (2002) Identification of a conserved domain of the HIV-1 transmembrane protein gp41 which interacts with cholesteryl groups. Biochim. Biophys. Acta 1567, 157-64.
41. Van Laethem, F., Liang, X., Andris, F., Urbain, J., Vandenbranden, M., Ruysschaert, J. M., Resh, M. D., Stulnig, T. M., and Leo, O. (2003) Glucocorticoids alter the lipid and protein composition of membrane rafts of a murine T cell hybridoma. J. Immunol. 170, 2932-9.
42. Schumann, J., Leichtle, A., Thiery, J., and Fuhrmann, H. (2011) Fatty acid and peptide profiles in plasma membrane and membrane rafts of PUFA supplemented RAW264.7 macrophages. PLoS One 6, e24066.
43. Spector, A. A. (1975) Fatty acid binding to plasma albumin. J. Lipid Res. 16, 165-79.
44. Benting, J., Rietveld, A., Ansorge, I., and Simons, K. (1999) Acyl and alkyl chain length of GPI-anchors is critical for raft association in vitro. FEBS Lett. 462, 47-50.
45. Peng, L., Minbo, H., Fang, C., Xi, L., and Chaocan, Z. (2008) The interaction between cholesterol and human serum albumin. Protein Pept. Lett. 15, 360-4.
46. Charbonneau, D. M., and Tajmir-Riahi, H. A. (2010) Study on the interaction of cationic lipids with bovine serum albumin. J. Phys. Chem. B 114, 1148-55.
47. Fishburn, C. S. (2008) The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97, 4167-83.
48. Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., and Damico, L. A. (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277, 35035-43.